167 related articles for article (PubMed ID: 26469969)
21. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
22. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
[TBL] [Abstract][Full Text] [Related]
25. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
Jayasooriya RG; Choi YH; Hyun JW; Kim GY
Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
[TBL] [Abstract][Full Text] [Related]
26. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
27. beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activity.
Kim MO; Moon DO; Kang CH; Kwon TK; Choi YH; Kim GY
Mol Cancer Ther; 2010 Apr; 9(4):833-43. PubMed ID: 20354117
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
29. Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
Khan M; Bi Y; Qazi JI; Fan L; Gao H
Mol Med Rep; 2015 Jan; 11(1):257-62. PubMed ID: 25333675
[TBL] [Abstract][Full Text] [Related]
30. Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway.
Lin T; Chen Y; Ding Z; Luo G; Liu J; Shen J
PLoS One; 2013; 8(5):e63966. PubMed ID: 23696862
[TBL] [Abstract][Full Text] [Related]
31. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
32. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation.
Yoon MJ; Kang YJ; Kim IY; Kim EH; Lee JA; Lim JH; Kwon TK; Choi KS
Carcinogenesis; 2013 Aug; 34(8):1918-28. PubMed ID: 23615398
[TBL] [Abstract][Full Text] [Related]
33. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
34. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.
Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U
Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694
[TBL] [Abstract][Full Text] [Related]
35. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
[TBL] [Abstract][Full Text] [Related]
36. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.
Oishi M; Iizumi Y; Taniguchi T; Goi W; Miki T; Sakai T
PLoS One; 2013; 8(2):e55922. PubMed ID: 23431365
[TBL] [Abstract][Full Text] [Related]
37. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
[TBL] [Abstract][Full Text] [Related]
39. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
40. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]